Skip to main content
Explore URMC

Theresa A. Bingemann, M.D.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Allergy, Immunology & Rheumatology, Pediatrics


Dr. Bingemann holds a dual appointment in the University of Rochester Medical Center’s Department of Pediatric Allergy & Immunology as well as the Department of Allergy, Immunology & Rheumatology. She completed her medical degree at Rutgers Medical School in New Jersey, where she was elected to the Alpha Omega Alpha medical honor society. She subsequently completed a combined residency in Internal Medicine and Pediatrics at Mount Sinai Hospital in New York City, and her Allergy and Immunology fellowship at the Mayo Clinic in Rochester, Minnesota. She currently practices clinical allergy & immunology for pediatric and adult patients. Her clinical interests include food allergy, environmental allergies, asthma, atopic dermatitis, medication allergy, urticaria (hives) and angioedema. Dr. Bingemann is the Program Director for the Allergy and Immunology fellowship training program and enjoys clinical research on food allergy and physician wellness.




    MD | New Jersey Medical School

    Post-doctoral Training & Residency

    06/26/2004 - 06/30/2006
    Fellowship in Allergy & Immunology at Mayo Foundation Rochester

    07/01/2001 - 06/30/2004
    Residency in Pediatrics, Internal Medicine at Mount Sinai School of Medicine

    07/01/2000 - 06/30/2001
    Internship in Pediatrics, Internal Medicine at Mount Sinai School of Medicine

    VIEW ALL expand_more

    Clinical Trials

    A 52-week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy ,

    Lead Researcher: Theresa Bingemann

    This study is designed to determine if there is a way to decrease sensitivity to peanuts in patients with a peanut allergy. There are 3 phases in this study: 1) Screening – 3 visits over to 4 weeks, 2) Treatment – 52-weeks - 17 visits with injections once a month, 3) Follow-up – 4 visits over 4 months. The study will involve skin prick tests/food challenges. You will be reimbursed for your participation. Eligibility: Ages 6-55, diagnosed with a peanut allergy, willing to commit to a partnership with our study team and the researchers at Novartis as we work to help patients with peanut allergy!

    View Study Details


    Journal Articles

    Russell AF, Bingemann TA, Cooke AT, Ponda P, Pistiner M, Jean T, Nanda A, Jobrack J, Hoyt AEW, Young MC. "The Need for Required Stock Epinephrine in All Schools: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee." The journal of allergy and clinical immunology. In practice.. 2023 Jan 27; Epub 2023 Jan 27.

    Pier J, Bingemann T, Badwal J, Rosloff D, Pasha M, Wang H, Lomas JM, Järvinen KM. "Food protein-induced enterocolitis syndrome: Healthcare utilization and referral patterns among a pediatric cohort." . 2023 4:1102410. Epub 2023 Feb 10.

    Sharma H, Nanda A, Bingemann TA, Khan DA, Sussman J, Kalman D, Mosnaim G. "Fellows in Training Wellness in Allergy and Immunology: AAAAI Workgroup Report." The journal of allergy and clinical immunology. In practice.. 2022 Oct 4; Epub 2022 Oct 04.